Maraviroc
94 interactions 1 explained in plain English 343 cited referencesMaraviroc is used along with other medications to treat a certain type of human immunodeficiency virus (HIV) infection in adults and children who weigh at least 4.4 lb (2 kg). Maraviroc is in a class of medications called HIV entry and fusion inhibitors. It works by decreasing the amount of HIV in the blood. Although m… Read the full Maraviroc drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Contraindicated
Maraviroc Atazanavir Reyataz Increased exposure of maraviroc Details Maraviroc Conivaptan Vaprisol Increased maraviroc exposure Details Maraviroc Darunavir Increased maraviroc exposure Details Maraviroc Delavirdine Rescriptor® Increased maraviroc concentrations Details Maraviroc Efavirenz Decreased maraviroc plasma concentrations and exposure (AUC) Details Maraviroc Ensitrelvir Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details Maraviroc Etravirine Intelence Decreased maraviroc plasma concentrations and exposure (AUC) Details Maraviroc Fosamprenavir Lexiva Increased maraviroc concentrations Details Maraviroc Levoketoconazole Recorlev Increased exposure of CYP3A4/P-gp substrate Details Maraviroc Phenobarbital Fidoquel Decreased levels of maraviroc Details Maraviroc Primidone Mysoline Decreased levels of maraviroc DetailsMajor
Maraviroc Abametapir Increased exposure of CYP3A4 substrate Details Maraviroc Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Maraviroc Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Maraviroc Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Maraviroc Ketoconazole Topical Extina® Foam Increased maraviroc exposure and an increased maraviroc-related adverse reactions Details Maraviroc Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Maraviroc Lenacapavir Injection Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Maraviroc Lenacapavir Oral Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Maraviroc Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Maraviroc Adagrasib Krazati Increased exposure to CYP3A/P-gp substrates Details Maraviroc Apalutamide Erleada Reduced maraviroc exposure and reduced efficacy of maraviroc Details Maraviroc Atidarsagene Autotemcel Lenmeldy Interference with the manufacturing of atidarsagene autotemcel Details Maraviroc Avacopan Tavneos Increased CYP3A4 substrate exposure Details Maraviroc Berotralstat Orladeyo Increased P-gp substrate exposure Details Maraviroc Boceprevir Increased maraviroc exposure Details Maraviroc Carbamazepine Carbatrol Reduced maraviroc exposure Details Maraviroc Ceritinib Zykadia Increased maraviroc exposure Details Maraviroc Clarithromycin Biaxin Increased maraviroc exposure Details Maraviroc Cobicistat Tybost Increased maraviroc exposure Details Maraviroc Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Maraviroc Duvelisib Copiktra Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Maraviroc Enzalutamide Xtandi Reduced maraviroc exposure Details Maraviroc Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Maraviroc Etuvetidigene Autotemcel An increased risk of interference with the manufacturing of etuvetidigene autotemcel Details Maraviroc Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Maraviroc Fexinidazole An increased CYP3A4 substrate exposure Details Maraviroc Fluconazole Diflucan Increased sensitive CYP3A4 substrates exposure Details Maraviroc Fosnetupitant Increased exposure of CYP3A4 substrate Details Maraviroc Fosphenytoin Cerebyx Reduced maraviroc exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist